Allied Health & Imaging · Independent exam preparation
Certified Clinical Transplant Nurse (CCTN®) Examination Study Guide
Practise graft surveillance, urgent complication recognition, medication safety and discharge decisions for ABTC CCTN nursing across adult and pediatric care.
By CertMedbry · Updated 31 October 2026
Recognize threatened graft function, distinguish surgical complications from rejection or medication toxicity, and build safe discharge plans. These 60 selected concepts emphasize decisions before surgery, immediately afterward and during lifelong follow-up. Representative cases include heart, lung, liver, kidney, pancreas, intestine and multiple-organ recipients, including children. The official CCTN Examination Content Outline defines the full scope; this selective guide does not replace it.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and professional pathway does this guide address?
This guide addresses the American Board for Transplant Certification Certified Clinical Transplant Nurse (CCTN®) examination for registered nurses caring for solid-organ transplant patients. It is not a nurse practitioner examination. ABTC lists 24 months of RN experience, including 12 months directly involved in solid-organ transplant care; the handbook describes 12 months of general RN experience plus an additional 12 months as a transplant nurse. CCTC®, CPTC®, CTP® and CTFC are separate examinations.
ABTC Certification Examinations · ABTC Candidate Handbook — currently linked August 13, 2026 file
How many questions are included, and how long is the examination?
The handbook specifies 175 questions and three hours for CCTN. Responses to 150 questions contribute to the score; the remaining 25 are unscored pretest questions. Treat every question as potentially scored. Breaks do not add testing time.
ABTC Candidate Handbook — currently linked August 13, 2026 file
How is the examination delivered, and what question styles are illustrated?
The handbook describes computer delivery at PSI test centers, with international centers available by arrangement. It illustrates conventional single-best-answer questions and explicitly labels a complex multiple-choice example using combinations of listed elements or phrases. Both formats present four answer choices: a combination item requires selecting one offered combination, rather than making separately scored multiple-response selections. One question appears at a time, and candidates can change answers, move backward and bookmark questions. The 20 questions here are independent single-best-answer learning drills.
ABTC Candidate Handbook — currently linked August 13, 2026 file
Which blueprint and effective date apply?
The CCTN Examination Content Outline is effective July 1, 2025. The linked handbook filename is dated August 13, 2026; that file date is distinct from the CCTN outline’s printed effective date. The July 1, 2026 CCTC and CPTC outlines elsewhere in the handbook belong to different examinations.
ABTC Candidate Handbook · ABTC Candidate Handbook — currently linked August 13, 2026 file
How are scored questions distributed across the six domains?
The published CCTN specifications are Pre-transplantation Care 9%/13 items; Care Immediately Post-transplantation 26%/39; Transplantation Management 26%/39; Pharmacological Therapeutics 17%/26; Education and Discharge 15%/23; and Professional Responsibilities 7%/10. Published percentages may be rounded. This guide allocates its 60 concepts as 5/16/16/10/9/4 and its questions and flashcards as 2/5/5/3/3/2. These selections approximate domain weights without reproducing the complete outline.
ABTC Candidate Handbook — currently linked August 13, 2026 file
What recipient ages and transplant types are within scope?
The official scope includes adult and pediatric recipients and all specified vascular organs: heart, lung, liver, kidney, pancreas and intestine, including multiple-organ transplants. The CCTN specifications identify 142 adult and eight pediatric scored items. Candidates whose experience centers on one organ should use the complete official outline to identify additional organ-specific study needs.
ABTC Candidate Handbook — currently linked August 13, 2026 file
What passing score or pass prediction can these materials provide?
ABTC describes criterion-referenced standard setting and overall pass/fail decisions. These materials assert no numerical passing threshold. Performance on the short learning drills identifies topics to revisit and does not predict an examination result.
ABTC Candidate Handbook — currently linked August 13, 2026 file
How should clinical references and jurisdictional differences be interpreted?
ABTC’s outline establishes examination scope; clinical references support teaching points. KDIGO’s 2009 recipient guideline provides older recommendations for kidney assessment, rejection treatment and infection prevention. These are identified as kidney recommendations and do not establish contemporary organ-specific dosing, drug targets or treatment durations. The 2024 BK consensus, 2017 CKD-MBD update and ISHLT guidance address their respective topics. OPTN donation examples use the United States context; NHS Blood and Transplant sources support complication recognition.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation · KDIGO_CKD_MBD_Guideline_r6.pdf · 2017_consensusdocument_ishlt_plgdpart1.pdf · HRSA OPTN — Living Donation FAQs
Independently authored preparation for ABTC’s registered-nurse-level Certified Clinical Transplant Nurse examination, distinct from its coordinator, procurement, preservationist and financial coordinator certifications.
Outline used: CCTN Examination Content Outline effective July 1, 2025, verified in the current handbook linked by ABTC on October 12, 2026. The linked handbook filename is dated August 13, 2026; that filename date is distinct from the outline's printed effective date. The assigned workbook label matches the official examination identity.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Pre-transplantation Care9%
1.How does residual kidney function shape preoperative assessment?
A kidney candidate may still produce urine despite inadequate filtration, so urine volume alone does not establish metabolic or volume stability. Assess the usual urine pattern alongside dialysis history, weight changes, blood pressure, edema, breathlessness and laboratory findings. Transplantation replaces kidney function but does not immediately erase cardiovascular disease or other consequences of kidney failure. The useful decision is whether the current condition differs from baseline and requires stabilization before surgery.
Apply it
A candidate reports normal urine volume but missed dialysis and now has increasing breathlessness and ankle edema. Compare current weight, examination findings and electrolytes with baseline, and communicate the deterioration before proceeding with routine surgical preparation.
Common pitfall: Assuming that continued urine production excludes serious kidney failure can conceal fluid overload or electrolyte abnormalities that matter immediately before anesthesia and transplantation.
2.How should adherence barriers influence candidate support?
Psychosocial assessment identifies circumstances that threaten safe treatment, including depression, limited understanding, medication costs and unreliable transport. A history of missed treatment should trigger exploration of causes and targeted support rather than a moral judgment. KDIGO recommends assessing adherence and barriers and providing education or counseling. Past nonadherence alone generally should not exclude a kidney candidate unless ongoing, health-compromising behavior persists despite appropriate intervention. Distinguish an addressable access problem from an unresolved pattern that continues after support.
Apply it
A candidate missed two visits because the only available bus arrived after clinic closed. Document the transport barrier, arrange a feasible appointment or transport option, and reassess attendance rather than describing the patient simply as unmotivated.
Common pitfall: Treating every missed appointment as deliberate refusal obscures remediable barriers and may produce an inaccurate assessment of the candidate’s ability to manage transplantation.
KDIGO 2020 Kidney Transplant Candidate Guideline — Executive Summary
3.What does a virtual crossmatch actually assess?
A virtual crossmatch compares a recipient’s characterized anti-HLA antibodies with the donor’s HLA typing to assess donor-specific immunologic incompatibility. It is an interpretation of existing laboratory information rather than a physical mixture of donor cells and recipient serum. Its reliability depends on adequate donor typing, appropriate antibody testing and awareness of sensitizing events since the sample was collected. A transfusion after the last antibody sample can therefore make an apparently reassuring assessment incomplete.
Apply it
A kidney candidate received a transfusion after the serum sample used for antibody assessment. Before accepting the compatibility interpretation as current, notify the histocompatibility laboratory so it can assess whether updated testing or additional crossmatching is needed.
Common pitfall: ABO compatibility does not establish HLA compatibility, and an old negative antibody assessment cannot automatically account for antibodies developing after a new sensitizing exposure.
4.Why review vaccines before immunosuppression begins?
Immunosuppression can reduce vaccine responses and make live vaccines unsafe, creating an advantage to reviewing immunization status during transplant evaluation. CDC guidance generally recommends giving indicated live vaccines at least four weeks and non-live vaccines at least two weeks before starting immunosuppressive therapy when feasible. These intervals do not justify independently delaying an urgent transplant. Identify missing vaccines early and distinguish vaccine safety from the likelihood of an adequate immune response.
Apply it
A stable candidate undergoing evaluation has incomplete vaccine records and no immediate operation planned. Obtain documentation and arrange review of indicated vaccines now, allowing the team to consider appropriate timing before immunosuppression makes vaccination more difficult.
Common pitfall: Waiting until discharge to investigate immunization status can miss opportunities for a stronger response and for live vaccines that may become contraindicated after transplantation.
5.Which interval changes matter when a waiting patient is called for surgery?
A prior transplant evaluation describes an earlier condition, not automatic readiness on the day of surgery. New infection symptoms, hospitalizations, medication changes and changes in functional status may alter perioperative risk. Ask specifically about events since the last assessment and communicate discrepancies before proceeding. For kidney candidates, active infection generally requires treatment before transplantation, although selected circumstances need individualized decisions. The discriminating cue is a meaningful interval change rather than the mere existence of prior clearance.
Apply it
A patient arriving for a kidney transplant reports a new productive cough and fever that began yesterday. Obtain current observations and promptly report the illness before routine preparation advances on the assumption that last month’s clearance remains sufficient.
Common pitfall: A completed evaluation and an available organ do not make a newly symptomatic candidate medically unchanged; concealing interval illness can undermine recipient safety.
KDIGO 2020 Kidney Transplant Candidate Guideline — Executive Summary
Care Immediately Post-transplantation26%
6.How is recorded postoperative fluid balance calculated?
Recorded balance equals documented intake minus documented output over the same interval. Include all stated intravenous and oral intake and all measured urine, drains and other losses. A positive number means recorded intake exceeded recorded output; it does not independently prove intravascular overload. Interpret the result with weight, blood pressure, examination and graft function. Unmeasured losses and incomplete records explain why arithmetic balance and the patient’s actual circulating volume may differ.
Apply it
Over six hours, a recipient receives 1,800 mL intravenously and drinks 200 mL. Urine is 1,450 mL and drain output is 150 mL. The recorded balance is positive 400 mL; assess clinical findings before interpreting its significance.
Common pitfall: Subtracting urine alone overstates balance when other measured losses are supplied. Conversely, adding guessed insensible losses changes a calculation that asks only for recorded balance.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
7.How should postoperative pain treatment be assessed and reassessed?
Assess pain location, onset, quality, intensity and effect on breathing, coughing, sleep and movement. Use an age-appropriate self-report scale when possible and a validated behavioral assessment when self-report is unavailable. Compare findings with the expected incision pattern; new severe graft-region, abdominal or chest pain requires assessment for complications. After prescribed analgesia, reassess both pain and function, together with sedation, respiratory rate, oxygenation and blood pressure. Kidney or liver dysfunction can alter medication handling, so organ function matters when reviewing an inadequate response or excessive sedation.
Apply it
A recipient splints the incision and cannot cough effectively. Provide prescribed analgesia and positioning support, then reassess the ability to breathe deeply and mobilize. If the patient becomes difficult to arouse or ventilation slows, prioritize airway and breathing assessment and activate the opioid-adverse-effect response pathway.
Common pitfall: A lower pain score accompanied by impaired arousal is not a satisfactory treatment response. Escalating analgesia without reassessing new pain can also conceal hemorrhage, ischemia or another surgical complication.
ABTC Candidate Handbook — currently linked August 13, 2026 file · NHS Blood and Transplant — Early risks of a liver transplant
8.How should an abrupt fall in kidney transplant urine output be assessed?
An abrupt output decline requires rapid assessment for measurement error, impaired drainage, reduced perfusion and graft complications. Check accessible catheter tubing and drainage while reassessing vital signs and the preceding fluid trend. Do not let a simple mechanical check delay notification when the change is substantial or the patient is unstable. Ultrasound forms part of the assessment of graft dysfunction because obstruction, collections and vascular problems require different responses from intrinsic kidney injury.
Apply it
Urine output falls suddenly after several hours of steady drainage. Check for visible tubing kinks and reassess blood pressure while notifying the transplant team. Persistent oliguria despite unobstructed drainage warrants urgent investigation rather than repeated observation alone.
Common pitfall: Calling every output decline rejection skips reversible mechanical and perfusion causes. Repeated catheter manipulation without authorization may delay evaluation and introduce unnecessary risk or trauma.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
9.What psychological support is needed after an early transplant complication?
A complication can produce fear of graft loss, guilt, disrupted expectations and distress about another procedure or prolonged hospitalization. Ask what the recipient understands and fears, acknowledge the reaction and explain the current findings and next steps in manageable portions. Include chosen support people with permission and assess sleep, coping and ability to participate in care. Persistent distress, withdrawal or hopelessness warrants psychosocial evaluation. New inattention, fluctuating awareness or disorientation also requires medical assessment for delirium, medication effects or physiologic deterioration.
Apply it
A recipient requiring temporary dialysis says the transplant has failed and refuses teaching. Clarify that delayed kidney function may recover, ask about the patient’s immediate concerns, agree on a small achievable care task and involve psychosocial support. Assess safety promptly if the patient expresses self-harm thoughts.
Common pitfall: Reassurance that everything will be fine dismisses uncertainty and does not assess distress. Conversely, labeling new confusion as anxiety can delay recognition of an acute medical problem.
ABTC Candidate Handbook — currently linked August 13, 2026 file · NIDDK — Kidney Transplant · KDIGO 2009 Kidney Transplant Recipient Guideline — Summary
10.Why can a kidney recipient need dialysis soon after transplantation?
Some transplanted kidneys do not function adequately immediately, and temporary dialysis may be needed while the graft recovers. Early dialysis therefore does not automatically establish irreversible graft loss or rejection. Continue prescribed immunosuppression and investigate graft dysfunction while managing electrolyte, fluid and metabolic needs. The clinical decision depends on the recipient’s condition rather than disappointment about needing dialysis. Persistent dysfunction still requires surveillance because delayed function and treatable graft complications can coexist.
Apply it
A recipient’s kidney has not begun providing adequate clearance, and the team orders dialysis for metabolic control. Explain that temporary support can be necessary during recovery while continuing graft monitoring and the prescribed antirejection regimen.
Common pitfall: Interpreting dialysis as proof that transplantation has failed may lead to misinformation or missed medications. Delayed function also must not become an excuse to ignore new deterioration.
11.Which findings make postoperative hyperkalemia particularly concerning?
Potassium can remain elevated when early graft clearance is inadequate, and tacrolimus can also contribute to hyperkalemia. Assess the potassium result with kidney function, medications, symptoms and electrocardiographic findings when indicated. A confirmed elevation with cardiac manifestations demands urgent escalation and ordered treatment; it should not be dismissed because transplantation has occurred. The useful distinction is between anticipating future graft improvement and managing the recipient’s current electrophysiologic risk without waiting for that improvement.
Apply it
A kidney recipient with poor early graft function has a confirmed potassium elevation and new electrocardiographic abnormalities. Escalate urgently and prepare prescribed treatment while reviewing potassium-containing fluids and medications; do not wait for tomorrow’s creatinine trend.
Common pitfall: Assuming a new kidney guarantees immediate potassium control overlooks delayed function and medication effects. Dietary advice alone is inadequate for a current potentially dangerous potassium disturbance.
DailyMed — PROGRAF prescribing information · NIDDK — Kidney Transplant
12.How is early bleeding after liver transplantation recognized?
Early postoperative bleeding may require transfusion or another operation. Interpret increasing bloody drainage alongside hemodynamic changes and serial blood counts rather than using one drain measurement in isolation. Tachycardia, falling blood pressure and a declining hemoglobin strengthen concern for clinically important blood loss. A drain is only one observation route; apparently limited output does not guarantee absence of internal bleeding. The priority is rapid assessment and surgical communication when the overall pattern suggests hemorrhage.
Apply it
A liver recipient develops increasing bright-red drainage, tachycardia and a downward blood-pressure trend. Activate urgent clinical review and prepare for prescribed resuscitation and laboratory assessment rather than waiting for the next scheduled drain-total entry.
Common pitfall: Treating all blood-stained drainage as expected after major surgery ignores the importance of rate and accompanying instability. A single initially acceptable hemoglobin does not override deterioration.
NHS Blood and Transplant — Early risks of a liver transplant
13.Why is hepatic artery thrombosis a time-sensitive complication?
A clot in the hepatic artery interrupts an essential blood supply to the transplanted liver and can threaten graft survival. Early assessment commonly includes ultrasound evaluation of blood flow. Loss of documented arterial flow requires urgent specialist assessment rather than routine trending alone. This is a vascular complication, so simply interpreting abnormal liver tests as rejection can delay the needed response. The discriminating cue is evidence of impaired graft perfusion, not a particular isolated enzyme value.
Apply it
An early liver-transplant Doppler study reports absent hepatic arterial flow. Immediately communicate the result through the transplant escalation pathway and anticipate urgent confirmatory or operative assessment instead of waiting for the next routine liver chemistry panel.
Common pitfall: Assuming that all early liver-test abnormalities reflect rejection can delay recognition of vascular compromise. Lack of dramatic symptoms does not make absent graft arterial flow reassuring.
NHS Blood and Transplant — Early risks of a liver transplant
14.What distinguishes a postoperative bile leak from routine drainage?
A bile leak allows bile to escape from the reconstructed biliary system rather than travel through its intended drainage route. It may produce bile-stained drain output or an intra-abdominal collection and can lead to infection or further intervention. Unexpected changes in drainage, abdominal symptoms and graft laboratory trends require assessment together. Recognizing a possible leak identifies a structural postoperative problem; it does not establish that rejection treatment is the appropriate response.
Apply it
A liver recipient’s drain changes from lightly blood-stained fluid to conspicuously bile-stained fluid. Record the appearance and amount, assess abdominal symptoms and vital signs, and promptly report the change for evaluation of a possible biliary leak.
Common pitfall: Focusing only on the total drain volume can miss a clinically important change in its character. Bile-stained output should not be normalized merely because a drain is present.
NHS Blood and Transplant — Early risks of a liver transplant
15.How does biliary narrowing differ from a bile leak?
A biliary stricture narrows the pathway carrying bile away from the liver, whereas a leak permits bile to escape outside that pathway. Both can affect graft recovery but call for assessment of biliary anatomy rather than assuming an immune cause. Jaundice or a cholestatic laboratory pattern can prompt investigation for impaired drainage; visible external bile loss is not required. The distinction helps the nurse communicate the suspected mechanism and anticipate diagnostic or drainage procedures.
Apply it
A liver recipient develops increasing jaundice without bile-stained external drainage. Explain that absence of a visible leak does not exclude a biliary complication, and communicate the laboratory and symptom trend for assessment of possible impaired bile drainage.
Common pitfall: Equating every biliary problem with external leakage misses obstruction. Conversely, jaundice alone does not prove a stricture because other graft disorders can produce similar findings.
NHS Blood and Transplant — Early risks of a liver transplant
16.How is primary lung graft dysfunction classified during the first 72 hours?
ISHLT grades primary graft dysfunction at T0, T24, T48 and T72 using chest imaging and PaO2/FiO2 together. Timing begins with final lung reperfusion; in bilateral transplantation this is second-lung reperfusion. T0 is assessed within six hours, and subsequent assessments use six-hour margins. No pulmonary edema means grade 0 at any ratio. With edema, a ratio above 300 is grade 1, 200–300 is grade 2 and below 200 supports grade 3. However, patients receiving FiO2 below 0.40 should not be assigned grade 3 from the ratio because it becomes unstable at low FiO2. Evaluate airway or vascular obstruction, cardiac dysfunction, infection, aspiration and hemorrhage as contributors.
Apply it
At T48, a ventilated recipient has bilateral pulmonary edema, PaO2 80 mmHg and FiO2 0.50. The ratio is 160, meeting grade 3 imaging and oxygenation criteria without the low-FiO2 limitation. Extracorporeal lung support for hypoxemia with compatible pulmonary edema is a separate grade 3 rule; record that support explicitly.
Common pitfall: An oxygen requirement alone does not determine the grade. The low-FiO2 qualification concerns ratio-based grading and should not be substituted for the extracorporeal-support rule. Extracorporeal support for a nonhypoxemic indication with clear imaging is considered ungradeable and recorded separately.
2017_consensusdocument_ishlt_plgdpart1.pdf · NHS Blood and Transplant — Early risks of a lung transplant
17.How should early circulatory deterioration in a heart recipient be approached?
Falling blood pressure accompanied by decreasing urine output, cool extremities or worsening mental status indicates threatened systemic perfusion. Distinguish impaired filling or blood loss from ventricular dysfunction, pulmonary vascular loading and rhythm-related deterioration. Review rhythm, hemodynamics, blood counts and drainage together; echocardiography assesses ventricular function and pericardial collections. Rising venous pressure with falling systemic perfusion can occur with tamponade or right ventricular dysfunction and is not diagnostic by itself. Clinical reference: https://www.ishlt.org/docs/default-source/standards-guidelines/2022_guideline_ishlt_careofhtxrecipients.pdf.
Apply it
After heart transplantation, pressure and urine output fall while venous pressure rises and chest drainage abruptly diminishes. Activate immediate surgical and critical-care assessment for impaired cardiac filling, including possible tamponade. Prepare for urgent echocardiography and ordered support without delaying stabilization.
Common pitfall: Reduced drainage can accompany retained blood or a blocked drain and does not exclude bleeding. Repeated fluid administration without reassessment may worsen congestion; neither hypotension nor oliguria alone establishes rejection or volume depletion.
ABTC Candidate Handbook — currently linked August 13, 2026 file
18.What does an abrupt glucose rise mean after pancreas transplantation?
A functioning pancreas graft supplies insulin, so a new glucose rise requires assessment of endocrine function as well as medication and stress effects. Review glucose trajectory, insulin requirement, abdominal findings and graft investigations. Vascular thrombosis can threaten the graft and requires urgent evaluation; pancreatic inflammation and rejection are additional possibilities. Tacrolimus can independently contribute to hyperglycemia. Glucose therefore signals functional deterioration but cannot establish its mechanism. Clinical reference: https://www.nhsbt.nhs.uk/organ-transplantation/pancreas/benefits-and-risks-of-a-pancreas-transplant/risks-of-a-pancreas-transplant/early-risks-of-a-pancreas-transplant/.
Apply it
A pancreas recipient who had required no insulin develops rising glucose and new abdominal pain. Report both changes immediately and anticipate urgent assessment of graft perfusion, including Doppler imaging as ordered, while treating hyperglycemia according to the prescription.
Common pitfall: Insulin can correct the glucose abnormality without resolving graft thrombosis or another underlying problem. Neither glucose nor a single pancreatic enzyme measurement establishes rejection, and medication effects should not be presumed before evaluating an abrupt painful change.
19.When does swallowing difficulty change postoperative feeding decisions?
Swallowing difficulties can occur after lung transplantation and may make eating or drinking unsafe. Coughing, choking or other concerns during intake should prompt assessment rather than reassurance based on successful extubation. Respiratory recovery and swallowing safety are separate questions. Follow the prescribed feeding plan and arrange appropriate swallowing evaluation when concerns arise. Alternative nutritional support may be needed temporarily, but a specific texture or route should follow assessment rather than an untested bedside assumption.
Apply it
An extubated lung recipient repeatedly coughs when offered water. Stop the unsupervised trial, assess the patient and obtain review under the postoperative swallowing pathway before continuing oral fluids or independently substituting a different drink consistency.
Common pitfall: Assuming that an awake, extubated patient can swallow safely may expose the lungs to aspiration. Simply thickening fluids without assessment does not establish a safe feeding plan.
20.How should intestinal losses be assessed in a pediatric transplant recipient?
Measure stool or ostomy losses alongside urine and drains, and express output relative to body weight. Rising losses with falling weight, reduced urine or circulatory deterioration suggest inadequate replacement and possible electrolyte disturbance. Review output character, feeds, medications and infectious symptoms. Increased output can accompany infection or rejection and may require stool investigations and endoscopic graft biopsies; volume alone does not identify the cause. Clinical references: https://www.chp.edu/-/media/chp/departments-and-services/transplant/documents/facts-about-intestinal-transplant.pdf and https://www.uhn.ca/Transplant/Intestine_Transplant_Program/Intestine_Transplant_Clinic/Documents/IntestineTransplant_manual.pdf.
Apply it
A 10-kg intestinal recipient produces 600 mL of ostomy output in 24 hours, equivalent to 60 mL/kg/day. Document the increase from baseline, include it in balance, assess urine, weight and perfusion, and arrange electrolyte and graft evaluation. This calculation is not a universal intervention threshold.
Common pitfall: Counting only urine can conceal major gastrointestinal losses. Increasing immunosuppression solely because output rose may worsen an unrecognized infection; providing replacement alone does not explain why graft output changed.
ABTC Candidate Handbook — currently linked August 13, 2026 file
21.Why must each graft be assessed separately after multiple-organ transplantation?
Different grafts provide different functions, so reassuring performance of one cannot establish the health of another. After simultaneous kidney–pancreas transplantation, urine output and creatinine assess kidney performance, while glucose and insulin requirements assess pancreatic endocrine function. Evaluate pancreatic vascular or inflammatory complications when indicated, and consider medication-related hyperglycemia. Clinical reference: https://www.nhsbt.nhs.uk/organ-transplantation/pancreas/benefits-and-risks-of-a-pancreas-transplant/risks-of-a-pancreas-transplant/early-risks-of-a-pancreas-transplant/.
Apply it
A kidney–pancreas recipient maintains stable creatinine but develops repeated glucose elevations and a new insulin requirement. Communicate the pancreatic functional change and assess medication and graft-related explanations instead of using kidney results to reassure the patient about both organs.
Common pitfall: Shared transplantation and immunosuppression do not guarantee identical graft behavior. Hyperglycemia alone also does not establish pancreas rejection or irreversible loss; additional clinical, imaging and sometimes tissue assessment is required.
Transplantation Management26%
22.Why can rejection occur without obvious symptoms?
Rejection can injure a graft before the recipient feels unwell. Kidney surveillance therefore depends on scheduled laboratory assessment as well as symptom reporting. Feeling well, maintaining urine output or having no graft pain does not replace follow-up testing. Explain that monitoring seeks early evidence of impaired function while potentially treatable injury is still developing. The decision to investigate follows objective changes and the clinical context, not a requirement that fever or pain must first appear.
Apply it
A kidney recipient wants to skip laboratory testing because energy and urine output are unchanged. Explain that rejection may be asymptomatic and help preserve the appointment rather than using wellness as evidence that surveillance can safely stop.
Common pitfall: Teaching only dramatic rejection symptoms may imply that normal daily activity guarantees graft health. Scheduled surveillance remains necessary even when the recipient reports feeling entirely well.
23.When is kidney graft biopsy useful, and what surveillance follows it?
KDIGO recommends kidney allograft biopsy for a persistent, unexplained creatinine increase. Ultrasound addresses anatomy and perfusion, drug levels assess exposure, and creatinine tracks filtration; tissue can distinguish intrinsic injuries requiring different treatment. Assess reversible causes before biopsy. After a percutaneous kidney biopsy, monitor vital signs, pain, the puncture site and urine for bleeding, with blood counts and imaging when indicated. New graft-region pain, gross hematuria, hypotension or a falling hemoglobin warrants prompt evaluation; serious bleeding may occur without visible external blood.
Apply it
After a kidney biopsy, a recipient develops worsening graft-region pain, dizziness and a downward blood-pressure trend. Escalate for possible bleeding, reassess urine and the site, and prepare ordered blood counts and imaging rather than assuming discomfort is expected.
Common pitfall: A small dry dressing does not exclude internal bleeding. These observations concern percutaneous kidney biopsy; surveillance after heart, lung, liver or intestinal biopsy must address that procedure’s distinct risks.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · KDIGO 2009 Kidney Transplant Recipient Guideline — Summary · Kidney Biopsy - NIDDK
24.How do cellular rejection, antibody-mediated rejection and tacrolimus toxicity differ?
T-cell-mediated rejection involves cellular immune injury; kidney biopsy may show interstitial inflammation, tubulitis or vascular involvement. Antibody-mediated rejection requires integrated interpretation of tissue findings, evidence of antibody interaction and donor-specific antibody testing. Donor-specific antibodies alone do not prove rejection. Tacrolimus toxicity can also impair filtration, sometimes with high exposure, tremor or hyperkalemia. KDIGO’s 2009 kidney guidance recommends corticosteroids initially for acute cellular rejection and lymphocyte-depleting treatment for resistant or recurrent episodes; antibody-mediated treatment can include plasma exchange, IV immunoglobulin and other selected agents.
Apply it
A kidney biopsy supports antibody-mediated injury and donor-specific antibodies are present. Explain that plasma exchange removes circulating antibodies and IV immunoglobulin modifies immune activity; this differs from treating cellular rejection primarily with corticosteroids. Monitor the selected therapy and graft response.
Common pitfall: A creatinine rise cannot classify rejection. Kidney pathology and treatment principles must not be transferred as identical diagnostic criteria or regimens to heart, lung, liver, pancreas or intestine recipients.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · Current Reference Guide to the Banff Classification - BANFF · OPTN Histocompatibility Laboratory Guidance Document · DailyMed — PROGRAF prescribing information
25.Which CMV serostatus pairing signals primary-infection risk?
A CMV-seropositive donor paired with a CMV-seronegative recipient creates an important risk of donor-derived primary CMV infection. A seropositive recipient can also develop CMV through reactivation, so prior antibodies do not eliminate risk. Use donor and recipient serostatus to understand the prevention and monitoring plan, not to diagnose active disease. Antibody status describes prior exposure; current viral detection and clinical findings answer different questions. Exact prevention regimens depend on the transplant context and current guidance.
Apply it
During handover, identify a donor-positive, recipient-negative CMV pairing as a major risk feature. Verify that the prevention and monitoring plan is documented rather than reassuring the recipient that a negative pretransplant antibody result means future CMV is unlikely.
Common pitfall: Confusing seronegativity with protection reverses the meaning of the mismatch. Seropositivity also should not be presented as immunity that excludes post-transplant CMV complications.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
26.How does CMV infection differ from CMV disease?
CMV infection means evidence of viral infection, which can occur without attributable symptoms. CMV disease adds clinical illness attributable to CMV, including a systemic syndrome or tissue-invasive involvement. A positive blood viral test alone therefore does not establish that CMV caused diarrhea, pneumonitis or another organ syndrome. Conversely, clinically significant illness warrants investigation rather than dismissal because a routine surveillance result was previously reassuring. Distinguishing viral detection from attributable disease improves communication and prevents unsupported diagnostic certainty.
Apply it
A recipient has detectable CMV DNA during surveillance but feels well. Describe the finding as evidence of infection requiring the prescribed response, rather than documenting CMV colitis without gastrointestinal symptoms, tissue findings or another basis for that diagnosis.
Common pitfall: Equating any positive CMV test with tissue-invasive disease overstates what blood testing proves. Symptoms in an immunosuppressed recipient also require assessment for competing infectious and noninfectious causes.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
27.When should kidney recipients undergo BK viral screening?
The 2024 international BK consensus recommends plasma BK DNAemia screening monthly until month nine and then every three months until two years after kidney transplantation; pediatric screening extends to three years. Screening seeks viral replication before advanced graft injury becomes apparent. Symptoms and creatinine alone are insufficient surveillance tools. These are kidney-transplant recommendations, not a universal schedule for every solid organ. Additional evaluation may be necessary when graft dysfunction or changes in immunosuppression alter the clinical picture.
Apply it
A clinically well pediatric kidney recipient reaches the second transplant anniversary. Check that BK surveillance planning accounts for the pediatric recommendation extending through three years rather than automatically stopping at the adult two-year screening endpoint.
Common pitfall: Using the adult stopping point for every child misses the guideline’s pediatric distinction. Screening for DNAemia should not be replaced solely by asking about urinary symptoms.
28.How does persistent BK DNAemia change immunosuppression decisions?
The 2024 BK consensus recommends confirmatory plasma testing within 2–3 weeks when BK DNA is 1,000–10,000 copies/mL. Reduction of immunosuppression is suggested after two qualifying measurements within that interval establish persistence. A single plasma result above 10,000 copies/mL or biopsy-proven BK nephropathy supports reduction without waiting for that low-level confirmation sequence. Use predefined steps and balance viral control against rejection risk. Unusually high immunologic risk or concurrent acute rejection requires individualized management rather than automatic reduction. Full consensus reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC11335089/.
Apply it
A kidney recipient without concurrent rejection or unusually high immunologic risk has plasma BK results of 1,700 and 2,300 copies/mL collected 2–3 weeks apart. Report the confirmed persistence for protocol-based immunosuppression reduction review. Continue viral and graft-function monitoring during the adjustment.
Common pitfall: Two positive tests without their interval do not fully describe the low-level confirmation criterion. Do not transfer plasma thresholds to urine results or apply a routine reduction pathway uncritically when acute rejection or high immunologic risk changes the balance.
29.Why does suspected PTLD require tissue diagnosis?
Post-transplant lymphoproliferative disorder can involve abnormal lymphoid proliferation under immunosuppression. EBV testing can inform risk and evaluation, but a viral result alone does not establish the tissue diagnosis or disease classification. KDIGO recommends histologic examination of tissue when PTLD is suspected. Imaging identifies involved sites and helps staging or biopsy planning, while tissue identifies the lymphoproliferative process. Persistent lymphadenopathy, systemic symptoms or organ lesions therefore require investigation that distinguishes supportive findings from diagnostic confirmation.
Apply it
A recipient develops persistent enlarged lymph nodes and weight loss, with detectable EBV DNA. Explain why tissue sampling remains necessary even after imaging: viral measurements and lesion distribution cannot independently confirm or classify PTLD.
Common pitfall: Neither EBV DNAemia nor metabolically active lesions are specific enough to establish PTLD alone. Serial monitoring should not replace appropriate tissue investigation of a persistent suspicious lesion.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
30.How should long-term skin cancer surveillance be structured?
Chronic immunosuppression increases skin cancer risk, so prevention and detection remain part of graft-recipient care. KDIGO’s kidney-recipient guidance supports sun protection, skin self-examination and periodic professional skin assessment, with particular attention to patients with previous lesions or skin cancer. A new changing or nonhealing lesion needs evaluation rather than waiting for symptoms of systemic illness. Surveillance complements sun avoidance and sunscreen; neither prevention nor a previously normal examination removes the need to assess new lesions.
Apply it
A kidney recipient reports a small lesion that repeatedly crusts and fails to heal. Arrange appropriate skin assessment and reinforce protection from ultraviolet exposure instead of waiting until the lesion becomes painful or the next transplant laboratory visit.
Common pitfall: A painless or small lesion is not automatically benign in an immunosuppressed recipient. Sunscreen use reduces exposure but does not replace examination of a persistent abnormality.
31.How do nonrenal rejection surveillance and biopsy monitoring differ?
Surveillance follows graft function: heart assessment includes rhythm, hemodynamics and ventricular function; lung assessment includes spirometry, oxygenation and respiratory symptoms; liver assessment includes liver chemistries after evaluating vascular and biliary causes; intestinal assessment includes output, feeding tolerance and endoscopic findings. Functional abnormalities are nonspecific, and rejection may require tissue assessment. Endomyocardial biopsy examines heart tissue; intestinal rejection evaluation uses endoscopic mucosal biopsies. Clinical references: https://www.ishlt.org/docs/default-source/standards-guidelines/2022_guideline_ishlt_careofhtxrecipients.pdf and https://www.uhn.ca/Transplant/Intestine_Transplant_Program/Intestine_Transplant_Clinic/Documents/IntestineTransplant_manual.pdf.
Apply it
After endomyocardial biopsy, monitor rhythm, blood pressure, venous access and symptoms suggesting perforation or tamponade; sudden hypotension requires immediate assessment. After intestinal endoscopy with biopsy, assess sedation recovery, abdominal findings and bleeding; severe new abdominal pain, rigidity or instability raises concern for perforation or significant bleeding.
Common pitfall: A creatinine-based surveillance model cannot represent every organ. Likewise, urine inspection after kidney biopsy does not substitute for rhythm and circulatory surveillance after heart biopsy or abdominal assessment after intestinal endoscopy.
NHS Blood and Transplant — Early risks of a liver transplant · NHS Blood and Transplant — Early risks of a lung transplant · Kidney Biopsy - NIDDK
32.What monitoring changes when rejection treatment intensifies immunosuppression?
Rejection treatment increases infection vulnerability as well as treating immune injury. High-dose corticosteroids require attention to glucose, blood pressure, mental status and infection findings. Lymphocyte-depleting treatment adds infusion-reaction and blood-count surveillance. Reassess the prescribed CMV and Pneumocystis prevention plan after intensified therapy rather than assuming the original discharge plan remains adequate. Follow organ-function trends to assess response while watching for treatment toxicity. A falling creatinine does not establish that treatment has been complication-free, and fever during therapy requires evaluation for infection as well as drug reactions.
Apply it
A kidney recipient receives corticosteroids followed by lymphocyte-depleting therapy for resistant cellular rejection. Track glucose, blood counts, observations and graft function, and confirm antimicrobial prevention arrangements. Communicate a new fever promptly rather than assuming it is part of rejection.
Common pitfall: Monitoring only graft improvement misses complications of treatment. Conversely, infection and rejection can coexist, so one diagnosis does not automatically exclude the other.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · DailyMed - THYMOGLOBULIN (anti-thymocyte globulin- rabbit injection, powder, lyophilized, for solution
33.When should bone-density testing be considered after kidney transplantation?
KDIGO’s 2017 CKD-MBD recommendation 5.5 suggests bone mineral density testing in kidney recipients with CKD G1T–G5T who have osteoporosis risk factors when the results will alter therapy. Testing assesses fracture risk; it does not by itself identify the underlying renal bone disorder or bone-turnover pattern. Interpret fracture history and density alongside calcium, phosphate, PTH, alkaline phosphatase and vitamin D findings. Selected patients may need additional evaluation, including consideration of bone biopsy when identifying the disorder would change treatment.
Apply it
A kidney recipient with a previous fragility fracture asks whether transplantation has cured the bone problem. Review osteoporosis risk and whether a density result would alter treatment, while assessing biochemical abnormalities that may influence the therapy selected.
Common pitfall: Do not attribute the 2017 results-will-alter-therapy criterion to the 2009 recipient summary. A low density result establishes neither the cause of bone disease nor a universal indication for the same medication in every recipient.
34.How should persistent diarrhea be evaluated in a transplant recipient?
Persistent diarrhea has infectious and noninfectious causes in transplant recipients, including medication-related gastrointestinal effects. KDIGO recommends investigating diarrhea for common and transplant-relevant causes rather than assuming a single explanation. Assess duration, severity, hydration, exposures and the medication list, and obtain ordered testing. Diarrhea can threaten the ability to maintain fluids and the oral regimen. The useful distinction is between recognizing mycophenolate as a possible contributor and establishing that it is the cause before changing immunosuppression.
Apply it
A recipient taking mycophenolate reports several days of frequent watery stools and reduced oral intake. Assess hydration and medication tolerance, notify the team and facilitate ordered infectious evaluation rather than advising the patient simply to stop mycophenolate.
Common pitfall: Attributing all diarrhea to mycophenolate can miss treatable infection. Conversely, naming infection without evaluation may overlook medication toxicity and delay a coordinated adjustment to the regimen.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · DailyMed — CELLCEPT prescribing information
35.What does new proteinuria add to kidney graft surveillance?
New proteinuria can signal clinically important kidney allograft disease even when the creatinine change is modest. It broadens concern beyond simple filtration loss and may prompt investigation for recurrent or new glomerular disease and other graft pathology. KDIGO identifies new-onset proteinuria as a biopsy indication. Establish the trend and quantify it as ordered rather than dismissing a urine abnormality because the patient feels well. Proteinuria is a clue to injury, not a diagnosis of its specific cause.
Apply it
A kidney recipient has newly detected proteinuria on repeated assessment while creatinine remains close to baseline. Communicate the new finding for evaluation rather than reassuring the patient that stable creatinine excludes a meaningful graft problem.
Common pitfall: Monitoring creatinine alone can miss another actionable graft signal. Proteinuria should not automatically be labeled recurrent native disease without evaluating competing causes and obtaining indicated diagnostic evidence.
36.How should renewed adherence problems be assessed after transplantation?
Adherence can change over time as treatment burden, mood, finances and caregiver arrangements change. Ask about missed doses using neutral, specific language and investigate the practical circumstances. A previously reliable recipient may develop a new barrier that requires intervention. KDIGO supports education, prevention and increased attention when nonadherence risk emerges. The useful decision is to identify which part of the regimen is failing and why, then match support to that mechanism instead of repeating generic warnings about rejection.
Apply it
A recipient who previously managed medication reliably begins missing evening doses after starting rotating shifts. Map the work schedule against the regimen and involve the team in a feasible support plan rather than assuming that earlier education remains sufficient.
Common pitfall: A general question such as whether everything is fine may miss specific dosing failures. Blame can suppress disclosure and reduce the accuracy of future adherence assessment.
37.Which infection patterns require urgent assessment rather than routine observation?
Fever with rigors, urinary symptoms, wound purulence or catheter-associated symptoms raises concern for bacterial infection; hypotension or altered mental status adds urgency. Obtain ordered cultures promptly without delaying urgent antimicrobial treatment in an unstable patient. Progressive dyspnea, dry cough and hypoxemia also require evaluation for opportunistic pneumonia, including Pneumocystis, rather than assuming a typical bacterial process. Oral white plaques suggest a different, localized fungal presentation and do not explain systemic instability. Immunosuppression can blunt inflammatory findings, so severe illness need not include a high fever.
Apply it
A recipient has shaking chills, new urinary discomfort and falling blood pressure. Arrange emergency assessment, communicate recent cultures and antimicrobial exposure, and facilitate ordered cultures and treatment. A separate recipient with progressive dry cough and hypoxemia needs urgent pulmonary investigation, including opportunistic causes.
Common pitfall: Absence of graft pain or marked fever does not exclude serious infection. A likely source guides investigation but should not delay resuscitation and treatment when the patient is unstable.
NIDDK — Kidney Transplant · KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Pharmacological Therapeutics17%
38.How do basiliximab and antithymocyte globulin differ as induction agents?
Basiliximab blocks the interleukin-2 receptor component CD25 on activated T cells and is nondepleting; antithymocyte globulin targets multiple lymphocyte antigens and causes lymphocyte depletion. KDIGO’s 2009 kidney guidance recommends an interleukin-2 receptor antagonist as first-line induction and a lymphocyte-depleting agent for higher immunologic risk. Antithymocyte globulin requires prescribed premedication and controlled infusion with close observation for cytokine-release reactions, hypotension and anaphylaxis; monitor blood counts for leukopenia and thrombocytopenia. Basiliximab also requires surveillance for hypersensitivity. Exact administration and count-based modifications are product-specific.
Apply it
During antithymocyte globulin administration, a recipient develops hypotension and respiratory symptoms. Stop the infusion and activate immediate assessment for a serious infusion reaction. Review counts before later prescribed doses rather than assuming every planned dose remains appropriate.
Common pitfall: Nondepleting does not mean free of allergic risk, and depleting induction does not replace maintenance therapy. Kidney induction preferences and individual product instructions are not universal rules for every organ.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · DailyMed - THYMOGLOBULIN (anti-thymocyte globulin- rabbit injection, powder, lyophilized, for solution · simulect-epar-product-information_en.pdf
39.How do CMV antivirals link indication, route and safety monitoring?
Ganciclovir and its oral prodrug valganciclovir inhibit CMV replication through inhibition of viral DNA polymerase; their role is antiviral prevention or treatment, not rejection suppression. Distinguish a prevention prescription from treatment of established disease. Kidney function affects dosing, while leukopenia and other cytopenias require blood-count surveillance, especially with concurrent mycophenolate. KDIGO’s older kidney guidance distinguishes oral treatment for selected nonsevere disease from intravenous ganciclovir for serious disease. Severe illness or unreliable gastrointestinal absorption requires route reassessment rather than assuming an oral prescription remains adequate.
Apply it
A recipient receiving valganciclovir develops falling neutrophils as kidney function worsens. Report both trends, verify the prescribed renal adjustment and review other marrow-suppressive medicines. Maintain CMV surveillance while the team selects a safe treatment or prevention plan.
Common pitfall: A preventive regimen must not be assumed to be an adequate treatment regimen. Neither viral detection nor declining counts justifies an unsupervised dose change that leaves the infection risk unaddressed.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · DailyMed - VALGANCICLOVIR tablet, film coated · DailyMed — CELLCEPT prescribing information
40.When should an immediate-release tacrolimus trough be collected?
A trough measures the concentration just before the next scheduled dose; for twice-daily immediate-release tacrolimus, this is approximately twelve hours after the preceding dose. Record the actual dose and sample times because a post-dose result cannot be interpreted as a true trough. KDIGO recommends twelve-hour trough monitoring for tacrolimus. Target concentrations vary with regimen, organ, time since transplantation and clinical circumstances, so sample validity must be checked before a result is compared with the prescribed target.
Apply it
A patient takes the morning immediate-release tacrolimus before arriving for a planned trough draw. Record the administration time and tell the team that the sample would be post-dose, allowing it to determine appropriate sampling and interpretation.
Common pitfall: Calling every morning tacrolimus sample a trough ignores timing. Adjusting treatment from a mislabeled post-dose concentration can create underexposure when the apparently high result prompts reduction.
KDIGO 2009 Kidney Transplant Recipient Guideline — Summary · DailyMed — PROGRAF prescribing information
41.Why can a CYP3A inhibitor increase tacrolimus toxicity?
Tacrolimus is metabolized through CYP3A pathways, so inhibitors can reduce its metabolism and raise exposure. The PROGRAF label identifies strong inhibitors such as clarithromycin and certain azole antifungals as important interaction risks. A newly added inhibitor therefore requires coordinated medication review, concentration monitoring and prescribed adjustment. The clinical clue is a temporal relationship between the new medicine and rising levels or toxicity findings. A medicine prescribed for infection can affect rejection therapy even though its intended treatment target is unrelated.
Apply it
A recipient develops tremor and a rising tacrolimus trough after clarithromycin is prescribed elsewhere. Immediately communicate the new drug and symptom timeline so the transplant team can address the interaction and arrange appropriate monitoring and adjustments.
Common pitfall: Assuming an antibiotic cannot affect immunosuppression overlooks metabolism interactions. Independent dose changes without a coordinated plan can exchange toxicity risk for inadequate rejection protection.
42.How can an enzyme inducer undermine tacrolimus treatment?
CYP3A inducers can increase tacrolimus metabolism and lower blood concentrations, risking inadequate immunosuppression. The PROGRAF label identifies agents such as rifampin and St John’s wort as important examples. Medication reconciliation must therefore include supplements as well as prescriptions. Starting or stopping an inducer can change exposure, so both events require review and monitoring. A low concentration should trigger assessment of interactions and dose timing alongside adherence rather than an automatic accusation that the recipient missed doses.
Apply it
A recipient’s tacrolimus level falls after starting an over-the-counter St John’s wort product. Identify the supplement as a potential interaction, document its use and arrange transplant-team review rather than assuming the prescribed tacrolimus dose was deliberately omitted.
Common pitfall: Calling a supplement natural does not establish pharmacologic safety. Stopping an interacting product without informing the team can also change exposure after compensatory dose adjustments.
43.What should be monitored during trimethoprim–sulfamethoxazole prophylaxis?
Trimethoprim–sulfamethoxazole is used to prevent Pneumocystis jirovecii pneumonia after transplantation. Monitor tolerance, rash, blood counts, kidney function and potassium. Potassium elevation is particularly relevant when tacrolimus or other potassium-raising medicines are also prescribed. Renal function influences the ordered regimen. A prevention prescription does not establish adequate treatment for new pneumonia, and symptoms such as progressive dyspnea or hypoxemia still require investigation. Following rejection treatment, confirm whether the prevention plan needs renewal or extension under the organ-specific protocol.
Apply it
A recipient taking tacrolimus and trimethoprim–sulfamethoxazole develops rising potassium. Report the medication combination and laboratory trend, assess for urgent manifestations and obtain regimen review rather than assuming the new kidney guarantees normal potassium handling.
Common pitfall: Do not stop prophylaxis without addressing the ongoing prevention need. If intolerance requires a replacement, the alternative must be selected for the patient’s risks rather than assumed to provide identical coverage.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · getFile.cfm · DailyMed — PROGRAF prescribing information
44.How do maintenance immunosuppressant mechanisms determine monitoring?
Tacrolimus binds FKBP12; the complex inhibits calcineurin, reducing interleukin-2 transcription and T-cell activation. Monitor trough exposure, kidney function, potassium, glucose and neurologic findings. Mycophenolate is converted to mycophenolic acid, which inhibits IMP dehydrogenase and de novo guanosine synthesis on which lymphocytes depend; monitor blood counts, gastrointestinal tolerance and reproductive safety. Corticosteroids alter glucocorticoid-receptor-mediated gene transcription and suppress inflammatory signaling; monitor glucose, blood pressure, mood, infection and bone health. Combining mechanisms improves rejection prevention but also increases cumulative infection risk.
Apply it
A recipient taking tacrolimus, mycophenolate and prednisone develops tremor, neutropenia and hyperglycemia. Investigate tacrolimus exposure for tremor, review mycophenolate and other marrow-suppressive drugs for neutropenia, and assess both tacrolimus and corticosteroid contributions to glucose elevation while evaluating competing causes.
Common pitfall: Different mechanisms do not make adverse effects exclusive to one drug. A tacrolimus level does not measure mycophenolate marrow toxicity or corticosteroid metabolic effects, and lowering one medicine does not automatically preserve the protection provided by the combination.
DailyMed — PROGRAF prescribing information · DailyMed — CELLCEPT prescribing information · KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
45.What concrete pregnancy precautions accompany CELLCEPT therapy?
Mycophenolate increases pregnancy-loss and congenital-malformation risk. Patients who can become pregnant need acceptable contraception during CELLCEPT treatment and for six weeks after stopping. Obtain a pregnancy test immediately before initiation, repeat it 8–10 days later and continue testing during routine follow-up. CELLCEPT may reduce oral-contraceptive effectiveness, so an additional barrier method is recommended with oral contraceptives. Review acceptable contraceptive options and pregnancy intentions explicitly. Any preconception medication transition must preserve graft protection through a coordinated alternative regimen.
Apply it
A recipient using an oral contraceptive plans pregnancy after stopping CELLCEPT. Explain the additional barrier-method recommendation, the six-week post-treatment contraception interval and the need for transplant and reproductive review before attempts begin. Suspected pregnancy requires prompt contact.
Common pitfall: Stopping CELLCEPT does not remove the six-week contraception requirement. Testing alone does not prevent pregnancy, and independently stopping all antirejection therapy creates a separate serious graft risk.
46.How should mycophenolate tablets and capsules be handled?
CELLCEPT tablets should not be crushed, and capsules should not be opened or crushed. Avoid inhalation of powder and direct contact with skin or mucous membranes because the active drug presents exposure hazards. Swallowing difficulty therefore requires pharmacy and transplant-team review for an appropriate formulation rather than improvised alteration. This is both a medication-administration issue and an exposure-prevention issue. Product-specific instructions matter because a convenient household method may violate the formulation’s handling requirements.
Apply it
A caregiver proposes opening mycophenolate capsules into yogurt for a recipient who cannot swallow them. Stop the proposed method and obtain pharmacy review for an appropriate prescribed formulation, explaining the handling risk and need to maintain reliable administration.
Common pitfall: Opening a capsule to make administration easier can expose the patient or caregiver to powder. The availability of another formulation does not authorize independent substitution or dose conversion.
47.What do falling blood counts mean during mycophenolate therapy?
Mycophenolate can cause blood dyscrasias, including leukopenia and neutropenia, so complete blood count surveillance is part of medication safety. A falling neutrophil count increases concern about infection vulnerability and may require prescribed interruption or reduction after evaluation. Other medicines and infections can also contribute, so the count is not proof of a single cause. Communicate the trend, symptoms and concurrent regimen together. Fever with marked neutropenia requires urgent assessment rather than routine follow-up alone.
Apply it
A recipient taking mycophenolate has progressively declining neutrophils and now reports fever. Escalate urgently, provide the count trend and current medicines, and facilitate evaluation rather than advising the patient to wait for the next scheduled blood draw.
Common pitfall: Viewing leukopenia as an expected harmless effect can delay infection assessment. Patients should not independently compensate by changing another immunosuppressant or stopping the entire regimen.
Education and Discharge15%
48.How does teach-back establish discharge understanding?
Teach-back asks the patient or caregiver to explain the plan in their own words, revealing how effectively the clinician communicated. A yes response to understanding does not demonstrate the ability to follow a complex regimen. Ask for concrete explanations or demonstrations, correct misunderstandings and check again using respectful language. Frame the exercise as checking the explanation rather than testing intelligence. Discharge readiness depends on demonstrated tasks and an achievable plan, not merely completion of a teaching checklist.
Apply it
After teaching the medication schedule, ask the recipient to show which medicines will be taken tomorrow morning and explain what happens before the laboratory draw. Correct the discovered timing error, then repeat the demonstration to confirm understanding.
Common pitfall: Repeating identical instructions more loudly does not address a misunderstanding. A signed education form also cannot substitute for checking whether the recipient can perform the required tasks.
49.What makes a home medication schedule usable?
A usable schedule connects each current medicine with its purpose, dose, timing and practical administration instructions. It must match the final discharge prescriptions rather than an earlier inpatient list. Antirejection therapy continues even when the recipient feels well, and changes require communication with the transplant team. Ask the patient to work through an ordinary day, including meals and planned monitoring. This reveals conflicts between written instructions and the household routine before a missed or duplicated dose occurs.
Apply it
A recipient has two medication lists with different tacrolimus instructions. Reconcile them against the final prescription, remove ambiguity from the active home schedule and ask the patient to explain the next planned doses before discharge.
Common pitfall: Providing several conflicting lists increases error risk even when each was once correct. A color-coded organizer is useful only if its contents match the current prescribed regimen.
NIDDK — Kidney Transplant · AHRQ TeamSTEPPS — Tool: Teach-Back
50.How should recipients use home monitoring records?
Home measurements become useful when recipients know what to measure, how to measure it and which changes require contact. Depending on the prescribed plan, records may include temperature, blood pressure, weight or glucose. Teach recipients to compare trends and bring records to follow-up while continuing scheduled laboratory surveillance. Home monitoring supplements professional assessment; it cannot diagnose rejection or exclude infection. An actionable plan identifies whom to contact and what to do when concerning symptoms or measurements appear.
Apply it
A recipient records daily weights but cannot explain when a change should be reported. Review the individualized action instructions, ask the patient to describe the response to a concerning trend and confirm access to the transplant contact number.
Common pitfall: Collecting numbers without an action plan creates false reassurance. A normal home measurement also should not overrule serious symptoms or justify canceling scheduled graft surveillance.
NIDDK — Kidney Transplant · AHRQ TeamSTEPPS — Tool: Teach-Back
51.Which food choices reduce infection risk after transplantation?
Immunosuppressed recipients are more vulnerable to severe foodborne illness. CDC guidance favors thoroughly cooked animal foods, pasteurized dairy products and safer preparation practices over raw or undercooked seafood, meat, eggs and unpasteurized products. Fresh appearance and a reputable restaurant do not eliminate microbial risk. Teach clean, separate, cook and chill practices alongside food selection. The goal is a sustainable safer diet rather than an unsupported rule that every fresh food or all restaurant eating must be avoided.
Apply it
A recipient plans a meal of raw oysters, unpasteurized cheese and cooked vegetables. Explain why the oysters and cheese are higher-risk choices and help substitute thoroughly cooked seafood and pasteurized cheese while retaining safely prepared vegetables.
Common pitfall: Calling raw seafood safe because it was freshly caught confuses freshness with pathogen control. Excessively broad food bans can distract from the preparation practices that actually reduce risk.
CDC — Safer Food Choices for People With Weakened Immune Systems
52.How should vaccination questions be handled after transplantation?
Non-live vaccines generally do not create the infection risk associated with replicating live vaccines, but immune responses may be reduced during immunosuppression. Most substantially immunocompromised recipients should not receive live vaccines without specialist determination. Teach patients to identify vaccine products and notify vaccinators about transplant treatment. Do not equate lower expected effectiveness with universal vaccine avoidance. The practical distinction is vaccine type, degree of immunosuppression and timing within a coordinated immunization plan.
Apply it
A recipient is offered a live intranasal influenza vaccine at a community clinic. Have the patient disclose the transplant regimen and obtain review for an appropriate non-live option rather than accepting the live product or rejecting all influenza vaccination.
Common pitfall: The statement that transplant recipients cannot have vaccines is overly broad. Conversely, treating every vaccine product for the same disease as interchangeable ignores important live-versus-non-live differences.
53.Why should household contacts stay appropriately vaccinated?
Vaccinating household contacts reduces opportunities to bring vaccine-preventable infections to an immunocompromised recipient. CDC recommends appropriate routine vaccination for close contacts, with product-specific precautions rather than blanket avoidance of all live vaccines. For example, if a varicella vaccine recipient develops a rash, direct contact with a susceptible immunocompromised person should be avoided until the rash resolves. Good hand hygiene after changing a rotavirus-vaccinated infant’s diaper addresses possible fecal shedding. Education should identify the specific precaution.
Apply it
A recipient’s family considers canceling a child’s routine vaccines to protect the transplant patient. Explain the protective value of household vaccination and review relevant precautions for varicella rash and diaper hygiene rather than recommending broad vaccine avoidance.
Common pitfall: Applying the recipient’s live-vaccine restrictions to every healthy household member can reduce protection. Specific post-vaccination precautions should be taught without implying that routine contact is universally dangerous.
54.How does a refill plan prevent interruption of immunosuppression?
Knowing medicine names does not ensure access to the next supply. Before discharge, establish where prescriptions will be obtained, whether coverage or authorization issues remain, how refills will be requested and whom to contact before a shortage. Antirejection medicines must continue as prescribed, including when the patient feels well. Ask the recipient to describe the actual next refill rather than offering only general adherence advice. A practical access plan converts education into a sustainable home regimen.
Apply it
A recipient can explain every medicine but has only three days of supply and an unresolved pharmacy authorization. Coordinate a confirmed supply and refill pathway before discharge rather than counting medication-name recall as sufficient readiness.
Common pitfall: Telling patients simply to take every dose ignores whether doses are available. Waiting until the final tablet is used leaves little time to resolve predictable access barriers.
NIDDK — Kidney Transplant · KDIGO 2020 Kidney Transplant Candidate Guideline — Executive Summary
55.How should pediatric caregivers demonstrate readiness for home care?
Pediatric transplant care depends on a reliable caregiver system as well as age-appropriate participation by the child. Use teach-back and demonstration with the people who will actually administer medicines and arrange monitoring. Each caregiver should understand the current plan and how handovers prevent omitted or duplicated doses. A child’s ability to name a medicine does not establish independent management readiness. The decision is whether responsibilities are explicit, achievable and demonstrated across the household’s actual caregiving arrangements.
Apply it
A child alternates between two caregivers’ homes. Ask both caregivers to demonstrate the medication routine and explain how they will document completed doses and share schedule changes, while involving the child at an appropriate developmental level.
Common pitfall: Teaching only the caregiver present during one hospital session leaves gaps when another person takes over. Age alone does not establish a child’s readiness for unsupervised medication responsibility.
AHRQ TeamSTEPPS — Tool: Teach-Back · ABTC Candidate Handbook — currently linked August 13, 2026 file
56.What should a recipient do when vomiting prevents medication retention?
Persistent vomiting can prevent adequate hydration and reliable retention of oral antirejection medicines. Teach recipients to contact the transplant team promptly when they cannot keep the regimen down and to report dose times, vomiting times and associated symptoms. Whether a dose should be repeated depends on the circumstances and prescribed instructions. An automatic extra dose can create excess exposure, while waiting through repeated missed doses can undermine graft protection. The home plan should make the next contact and action clear.
Apply it
A recipient vomits after morning medicines and cannot retain subsequent fluids. Ask for the medication and vomiting timeline and direct prompt transplant-team assessment rather than advising an automatic repeat of every medicine or waiting until tomorrow.
Common pitfall: Assuming that every vomited dose was completely unabsorbed can lead to duplicate exposure. Persistent inability to retain fluids or immunosuppression requires more than routine reassurance.
NIDDK — Kidney Transplant · AHRQ TeamSTEPPS — Tool: Teach-Back
Professional Responsibilities7%
57.How is a living donor’s confidential withdrawal protected?
In the United States living-donation framework, donation is voluntary and a potential donor may withdraw. OPTN patient guidance explains that the donor’s decision not to proceed can remain confidential. A nurse should respond privately, involve the donor team or independent donor advocate and avoid disclosing the donor’s reason to the intended recipient without permission. The ethical distinction is between supporting an informed voluntary decision and using the recipient’s medical need to pressure a donor to continue.
Apply it
A potential donor privately says family pressure has become overwhelming and asks to stop evaluation without explaining the reason to the recipient. Facilitate confidential contact with the donor team and advocate, respecting the request rather than arranging a joint persuasion meeting.
Common pitfall: Promising the recipient access to the donor’s private explanation compromises voluntariness and confidentiality. A completed evaluation does not remove the donor’s ability to withdraw.
58.When may donor and recipient information be shared?
Donor and recipient information sharing requires attention to what is clinically necessary, what each person has authorized and the applicable program process. OPTN guidance recommends defined approaches to consent and communication rather than assuming that donation creates unrestricted access to another person’s record. Distinguish information required for safe transplantation from optional personal updates or identifying details. A request from a grateful recipient or concerned relative does not by itself establish permission to disclose protected information.
Apply it
A recipient asks a nurse for the living donor’s unrelated mental-health history. Check the authorized information-sharing process and involve the appropriate team rather than releasing details merely because the two people are related and participated in the same transplant.
Common pitfall: A family relationship or shared transplant experience does not create blanket authorization. Equally, confidentiality should not be used to bypass the program’s required communication of relevant clinical risks.
HRSA OPTN — Guidance for Donor and Recipient Information Sharing
59.How does kidney paired donation address incompatibility?
Kidney paired donation can help when an intended living donor and recipient are incompatible. Participating pairs are matched so a donor gives to a compatible recipient in another pair or chain, while the intended recipient receives a compatible kidney from another donor. It is an exchange arrangement rather than a guarantee that the original pair becomes biologically compatible. Evaluation, voluntariness and compatibility assessment remain necessary. The nurse can explain the pathway without promising a match or a particular waiting time.
Apply it
An otherwise suitable donor cannot donate directly to the intended kidney recipient because of incompatibility. Explain paired donation as a possible alternative matching pathway and refer the pair for program assessment rather than declaring that living donation is no longer possible.
Common pitfall: Paired donation changes who donates to whom; it does not eliminate donor assessment or compatibility requirements. Participation also does not guarantee that an acceptable exchange will be found.
60.How can teach-back improve transplant discharge quality?
Teach-back makes misunderstanding visible, allowing a team to improve communication before errors reach home. A useful quality measure distinguishes completion of education from demonstrated comprehension of a specific task. Review recurring errors, revise explanations or materials and reassess understanding after the change. This is a systems approach to communication rather than a count of supposedly difficult patients. A higher number of discovered misunderstandings may initially reflect better detection, so interpret results with the assessment process and follow-up performance.
Apply it
A unit finds that many recipients misunderstand laboratory-day tacrolimus timing despite signed teaching records. Standardize an explanation, require a patient demonstration of the next laboratory morning and compare successful demonstrations before and after the educational change.
Common pitfall: Counting distributed leaflets measures activity rather than comprehension. A fall in reported errors is not persuasive if the team also stopped asking patients to demonstrate understanding.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Devote the greatest study time to immediate postoperative care and ongoing transplantation management, which together account for 52% of the published blueprint.
- Distinguish perfusion and drainage problems, cellular and antibody-mediated rejection, infection and medication toxicity when graft function changes.
- Assess pain-treatment response through comfort, function, sedation and ventilation, and provide psychological support after complications.
- Practise heart circulatory assessment, pancreas glucose trends, pediatric intestinal losses and independent surveillance of each graft in multiple-organ recipients.
- Use imaging and PaO2/FiO2 together for primary lung graft dysfunction, including the low-FiO2 qualification and separate extracorporeal-support rule.
- Connect maintenance-drug mechanisms and antimicrobial indications with blood counts, kidney function, potassium, glucose and immunosuppressant exposure.
- Compare organ-specific rejection surveillance and biopsy risks, rehearse reproductive precautions and require discharge demonstrations.
- Use the complete official outline to study topics and organ-specific practices beyond these selected concepts.
A practical preparation plan
1. Map experience against the full CCTN outline
Mark each official domain and organ context as familiar, partly familiar or unfamiliar. Identify gaps outside your usual transplant population, including pediatric recipients, and schedule those topics explicitly.
2. Build postoperative comparison cases
Compare impaired drainage, poor perfusion and intrinsic graft injury. Include heart filling or pumping problems, liver vascular and biliary complications, pancreas dysfunction and pediatric intestinal fluid losses. Add pain reassessment and support for distress after complications.
3. Connect findings to diagnostic limits
State what each finding establishes: creatinine tracks filtration, imaging evaluates anatomy or perfusion, antibody and viral testing supply specific laboratory evidence, and biopsy identifies tissue pathology. Compare surveillance and post-biopsy observations across organs.
4. Rehearse treatment and medication monitoring
Explain how calcineurin inhibitors, mycophenolate and corticosteroids suppress immune responses. Compare rejection treatment principles, induction reactions, antiviral cytopenias, Pneumocystis prophylaxis, interactions, tacrolimus sampling and CELLCEPT reproductive precautions.
5. Demonstrate a complete discharge day
Explain the home regimen, laboratory morning, refill process, safer food choices and response to fever or vomiting. Include the actual caregivers and require demonstration of critical tasks.
6. Use the drills to identify reasoning gaps
Answer the 20 questions before reading explanations. For each error, identify the decisive cue and why the selected alternative failed, then use flashcards to revisit the underlying mechanism.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABTC Candidate Handbook
- ABTC Certification Examinations
- ABTC Candidate Handbook — currently linked August 13, 2026 file
- OPTN Histocompatibility Laboratory Guidance Document
- KDIGO 2020 Kidney Transplant Candidate Guideline — Executive Summary
- KDIGO 2009 Kidney Transplant Recipient Guideline — Summary
- KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
- NHS Blood and Transplant — Early risks of a liver transplant
- NHS Blood and Transplant — Early risks of a lung transplant
- NIDDK — Kidney Transplant
- The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
- DailyMed — PROGRAF prescribing information
- DailyMed — CELLCEPT prescribing information
- CDC — Altered Immunocompetence
- CDC — Safer Food Choices for People With Weakened Immune Systems
- AHRQ TeamSTEPPS — Tool: Teach-Back
- HRSA OPTN — Living Donation FAQs
- HRSA OPTN — Guidance for Donor and Recipient Information Sharing
- KDIGO_CKD_MBD_Guideline_r6.pdf
- 2017_consensusdocument_ishlt_plgdpart1.pdf
- Current Reference Guide to the Banff Classification - BANFF
- DailyMed - THYMOGLOBULIN (anti-thymocyte globulin- rabbit injection, powder, lyophilized, for solution
- DailyMed - VALGANCICLOVIR tablet, film coated
- simulect-epar-product-information_en.pdf
- getFile.cfm
- Kidney Biopsy - NIDDK
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.